The deal priced at low end of $5.75-$6.25 target range. JPMorgan, TD Cowen and Piper Sandler are acting as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics $75M Spot Secondary; price range $5.75-$6.25
- Protara Therapeutics announces $75M common stock offering
- Protara’s TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating
- Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial
- Buy Recommendation for Protara Therapeutics Driven by Promising TARA-002 Developments and Strategic Market Positioning